Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery.

Profound technological advances in the drug discovery process have led to the identification of an increasingly large number of promising compounds at the hits-to-leads stage. Higher-throughput pharmacokinetic screens have therefore been developed to enhance the tractability of selected leads and minimize the risk of failure in the later stages of drug development.

[1]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[2]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[3]  G. Tucker,et al.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  D. Lewis,et al.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.

[5]  Donald W. Miller,et al.  Brain uptake of drugs : the influence of chemical and biological factors , 1992 .

[6]  E. Gordon,et al.  Combinatorial chemistry and molecular diversity in drug discovery , 1998 .

[7]  K. Adkison,et al.  Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. , 1997, Journal of medicinal chemistry.

[8]  T. Olah,et al.  The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.

[9]  M. Ackland.  Correlation between site specificity and electrophilic frontier values in the metabolic hydroxylation of biphenyl, di-aromatic and CYP2D6 substrates: a molecular modelling study. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  Peter J. Eddershaw,et al.  Advances in in vitro drug metabolism screening , 1999 .

[11]  Harpreet S. Chadha,et al.  Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. , 1995, Drug design and discovery.

[12]  Dinesh V. Patel,et al.  Strategy and Tactics in Combinatorial Organic Synthesis. Applications to Drug Discovery , 1996 .

[13]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[14]  Han van de Waterbeemd,et al.  Estimation of Caco‐2 Cell Permeability using Calculated Molecular Descriptors , 1996 .

[15]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[16]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[17]  Ajay,et al.  Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.

[18]  Rodrigues Ad,et al.  Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. , 1997 .

[19]  M H Tarbit,et al.  High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.

[20]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[21]  S. Toon,et al.  Structure-pharmacokinetic relationships among the barbiturates in the rat. , 1983, The Journal of pharmacology and experimental therapeutics.

[22]  S. Hirono,et al.  Simple Method of Calculating Octanol/Water Partition Coefficient. , 1992 .

[23]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[24]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[25]  Walter A. Korfmacher,et al.  HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .

[26]  Evans,et al.  Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.

[27]  John Bradshaw,et al.  Identification of Biological Activity Profiles Using Substructural Analysis and Genetic Algorithms , 1998, J. Chem. Inf. Comput. Sci..

[28]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[29]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[30]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[31]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[32]  Brian Hudson,et al.  Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..

[33]  W. Rubas,et al.  Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. , 1996, Journal of pharmaceutical sciences.

[34]  B. Kennedy,et al.  Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.